PulseAugur
EN
LIVE 04:14:56

OncoTraj benchmark launched for lung cancer drug resistance prediction

By PulseAugur Editorial · [2 sources] ·

Researchers have introduced OncoTraj, a new public benchmark dataset designed to advance the prediction of drug resistance in EGFR-mutant non-small-cell lung cancer. The dataset comprises longitudinal patient trajectories from 813 individuals treated with osimertinib, harmonized from three clinical-genomic sources. OncoTraj includes three defined tasks for model evaluation: predicting progression at 12 months, estimating time to progression, and classifying resistance mechanisms. Initial evaluations with various baseline models, including transformers, indicate that current single-timepoint snapshot features limit predictive accuracy, suggesting a need for serial ctDNA data in future iterations. AI

IMPACT Establishes a standardized benchmark for AI models in predicting cancer drug resistance, potentially accelerating clinical applications.

RANK_REASON The cluster contains a research paper introducing a new benchmark dataset and evaluation tasks.

Read on arXiv cs.LG →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

OncoTraj benchmark launched for lung cancer drug resistance prediction

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
The cluster contains a research paper introducing a new benchmark dataset and evaluation tasks.
Source corroboration
2 independent sources
Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics
paper, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
113 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [2]

  1. arXiv cs.LG TIER_1 English(EN) · Abhijoy Sarkar, Aarchi Singh Thakur ·

    OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib

    arXiv:2606.11144v1 Announce Type: new Abstract: Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating co…

  2. arXiv cs.LG TIER_1 English(EN) · Aarchi Singh Thakur ·

    OncoTraj: a public benchmark for longitudinal resistance prediction in EGFR-mutant non-small-cell lung cancer on osimertinib

    Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitud…

RELATED TOPICS